Contributions
Abstract: P921
Type: Poster
Abstract Category: Clinical aspects of MS - 8 Clinical assessment tools
Background: MS PATHS (Multiple Sclerosis Partners Advancing Technology and Health Solutions) is a network of 10 healthcare institutions in the United States and Europe. Patients in MS PATHS complete adaptations of the Multiple Sclerosis Functional Composite (MSFC) using an iPad-based device, to provide clinicians with objective, quantitative performance outcomes (PerfOs), without disrupting provider workflow or adding cost. This is the first attempt to engage patients and leverage technology to capture functional performance metrics during routine care.
Objectives: To establish the cross-sectional validity of functional performance data generated by MS patients during routine office visits.
Methods: Immediately prior to their medical visit, patients completed the Multiple Sclerosis Performance Test (MSPT) to provide a structured history, 12 scales of the Quality of Life in Neurological Disorders (Neuro-QoL), and electronic adaptations of the MSFC: the processing speed test (PST); manual dexterity test (MDT); and walking speed test (WST). Data was collected, analyzed, and stored electronically, eliminating the need for case report forms or data entry. Validity of the PerfOs, and relationship to Neuro-QoL and Patient Derived Disease Steps (PDDS) were assessed using descriptive statistics and Spearman's correlations.
Results: 1353 MS patients had mean (SD) age of 48.9 yrs (12), mean (SD) disease duration 12.2 yrs (9.4), 72% were female and 85% were white. Mean (SD, range) PST was 45.9 correct (13.2, 4-86), mean (SD, range) MDT was 28.8 secs (7.1, 17.2-55.8), mean (SD, range) WST was 8.1 secs (5.4, 2-52.5) and mean (SD, range) PDDS was 2.4 (2.2, 0-8). Correlations among the measures (Spearman r values) were -.64 (p< .001) (PSTxMDT), .57 (p< .001) (WSTxMDT) and -.47 (p< .001) (PSTxWST). Correlations with the PDDS were .61 (p< .001) (MDT), .63 (p< .001) (WST) and -.48 (p< .001) (PST). Correlations between Neuro-QoL scores and PerfOs were statistically significant (p< .001) for all pairs. All correlations were consistent with values reported in the literature for MSFC and EDSS.
Conclusions: Correlations between MSPT derived PerfOs were similar to previously published correlations between MSFC components representing the same dimensions, and the relationship between MSPT PerfOs and PDDS were similar to published correlations between MSFC outcomes and EDSS. These results support the validity of self-administered neuroperformance testing in a routine MS care setting.
Disclosure: Project funded by Biogen, Inc.
Author disclosures:
Robert Bermel has received consulting fees from Biogen, Novartis, Genentech, Genzyme and Mallinckrodt, and is part contributor to the intellectual property used in the MSPT.
James R. Williams, Carl de Moor, Glenn A. Phillips, Himanshu Pandya and Richard Rudick are employees of, and stockholders in, Biogen.
Abstract: P921
Type: Poster
Abstract Category: Clinical aspects of MS - 8 Clinical assessment tools
Background: MS PATHS (Multiple Sclerosis Partners Advancing Technology and Health Solutions) is a network of 10 healthcare institutions in the United States and Europe. Patients in MS PATHS complete adaptations of the Multiple Sclerosis Functional Composite (MSFC) using an iPad-based device, to provide clinicians with objective, quantitative performance outcomes (PerfOs), without disrupting provider workflow or adding cost. This is the first attempt to engage patients and leverage technology to capture functional performance metrics during routine care.
Objectives: To establish the cross-sectional validity of functional performance data generated by MS patients during routine office visits.
Methods: Immediately prior to their medical visit, patients completed the Multiple Sclerosis Performance Test (MSPT) to provide a structured history, 12 scales of the Quality of Life in Neurological Disorders (Neuro-QoL), and electronic adaptations of the MSFC: the processing speed test (PST); manual dexterity test (MDT); and walking speed test (WST). Data was collected, analyzed, and stored electronically, eliminating the need for case report forms or data entry. Validity of the PerfOs, and relationship to Neuro-QoL and Patient Derived Disease Steps (PDDS) were assessed using descriptive statistics and Spearman's correlations.
Results: 1353 MS patients had mean (SD) age of 48.9 yrs (12), mean (SD) disease duration 12.2 yrs (9.4), 72% were female and 85% were white. Mean (SD, range) PST was 45.9 correct (13.2, 4-86), mean (SD, range) MDT was 28.8 secs (7.1, 17.2-55.8), mean (SD, range) WST was 8.1 secs (5.4, 2-52.5) and mean (SD, range) PDDS was 2.4 (2.2, 0-8). Correlations among the measures (Spearman r values) were -.64 (p< .001) (PSTxMDT), .57 (p< .001) (WSTxMDT) and -.47 (p< .001) (PSTxWST). Correlations with the PDDS were .61 (p< .001) (MDT), .63 (p< .001) (WST) and -.48 (p< .001) (PST). Correlations between Neuro-QoL scores and PerfOs were statistically significant (p< .001) for all pairs. All correlations were consistent with values reported in the literature for MSFC and EDSS.
Conclusions: Correlations between MSPT derived PerfOs were similar to previously published correlations between MSFC components representing the same dimensions, and the relationship between MSPT PerfOs and PDDS were similar to published correlations between MSFC outcomes and EDSS. These results support the validity of self-administered neuroperformance testing in a routine MS care setting.
Disclosure: Project funded by Biogen, Inc.
Author disclosures:
Robert Bermel has received consulting fees from Biogen, Novartis, Genentech, Genzyme and Mallinckrodt, and is part contributor to the intellectual property used in the MSPT.
James R. Williams, Carl de Moor, Glenn A. Phillips, Himanshu Pandya and Richard Rudick are employees of, and stockholders in, Biogen.